FDA label
What is Keppra used for?
Keppra contains levetiracetam. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Keppra lists 3 uses: Partial-Onset Seizures; Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy; Primary Generalized Tonic-Clonic Seizures.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Keppra?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Keppra, tablet, film coated
Indications and Usage, quoted from the label by UCB, Inc. (NDA021035). Cross-references to other label sections are left out.
Partial-Onset Seizures
KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy
KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy.
Primary Generalized Tonic-Clonic Seizures
KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
Source: DailyMed label, set id 3ca9df05-a506-4ec8-a4fe-320f1219ab21, version 36, effective January 28, 2026. NDC 50474-594, one of 4 listings for this product.
Keppra, tablet, film coated, extended release
Indications and Usage, quoted from the label by UCB, Inc. (NDA022285). Cross-references to other label sections are left out.
KEPPRA XR ®is indicated for the treatment of partial-onset seizures in patients 12 years of age and older.
Source: DailyMed label, set id 2919e43b-69a8-434c-a2d2-1f3ecd7554c0, version 31, effective June 24, 2025. NDC 50474-598, one of 2 listings for this product.
Keppra, injection, solution, concentrate
Indications and Usage, quoted from the label by UCB, Inc. (NDA021872). Cross-references to other label sections are left out.
Partial-Onset Seizures
KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy
KEPPRA is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy.
Primary Generalized Tonic-Clonic Seizures
KEPPRA is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
Limitations of Use
KEPPRA injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.
Source: DailyMed label, set id c6d5784d-abf9-45fe-ac5a-d5c53bd50f7e, version 29, effective June 30, 2025. NDC 50474-002, one of 1 listing for this product.
Questions
What is Keppra used for?
The FDA label for Keppra lists 3 uses: Partial-Onset Seizures; Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy; Primary Generalized Tonic-Clonic Seizures.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Keppra
- Is Keppra a controlled substance?Federal schedule
- Generic for KeppraFDA Orange Book
- What is Levetiracetam used for?FDA label uses
- Is Levetiracetam a controlled substance?Federal schedule
- Generic for Keppra XRFDA Orange Book
- Generic for SpritamFDA Orange Book
- NDC 50474-001Keppra NDC record
- NDC 50474-002Keppra NDC record
- NDC 50474-594Keppra NDC record